首页> 美国卫生研究院文献>Thorax >Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease.
【2h】

Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease.

机译:评估慢性阻塞性气道疾病患者气道阻塞的可逆性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Spirometry before and after an inhaled beta agonist or a course of oral prednisolone is widely used to detect reversible airflow limitation in patients with chronic obstructive lung disease. How many of these patients have a response and how the response to beta agonists relates to the response to corticosteroids is not clear. In 127 outpatients (mean (SD) FEV1 0.92 (0.38) 1) who had a clinical diagnosis of chronic obstructive lung disease (continuous breathlessness for more than six months and an FEV1/forced vital capacity (FVC) ratio less than 60%) and who appeared to be stable, the change in FEV1 was measured after salbutamol 200 micrograms from a metered dose inhaler and 5 mg from a nebuliser. Symptoms and spirometric values were recorded before and after two weeks of oral prednisolone 30 mg. Reversibility was defined as a response in FEV1 of 15% or more from baseline alone and as a 15% change and a minimum increase of at least 200 ml. The latter gave results that showed greater internal consistency between the drug regimens. On the basis of this criterion 56 patients (44%) had no response to salbutamol or prednisolone, 71 responded to salbutamol (including all 27 steroid responders), and 25 patients had a response to salbutamol 5 mg but not to 200 micrograms. In general, the largest increase in FEV1 after salbutamol occurred in the subjects with greatest improvement after prednisolone. Subjects showing a response in FEV1 after two weeks' prednisolone had a fall in total symptom score, unlike those who had no response to any treatment or a response to salbutamol only. These data show that reversibility in response to beta agonists is common in patients diagnosed on clinical grounds as having stable chronic obstructive lung disease, that it can be substantial, and that it is best detected by using a larger dose of salbutamol. Salbutamol responders were those most likely to improve after a trial of oral prednisolone. Allowance should be made for the variability of FEV1 in the calculation of the percentage response at low baseline values (less than 1 litre).
机译:吸入性β受体激动剂或口服强的松龙疗程前后的肺活量测定法广泛用于检测慢性阻塞性肺疾病患者的可逆气流受限。这些患者中有多少有反应以及对β激动剂的反应与对皮质类固醇的反应如何相关尚不清楚。在127例临床诊断为慢性阻塞性肺疾病(连续呼吸超过六个月且FEV1 /强迫肺活量(FVC)比率小于60%)的门诊患者(平均(SD)FEV1 0.92(0.38)1)中,对于稳定的患者,在从计量吸入器吸入200毫克沙丁胺醇和从雾化器吸入5毫克沙丁胺醇后,测量FEV1的变化。口服泼尼松龙30 mg的两周前后记录症状和肺活量。可逆性定义为:FEV1中仅相对于基线的反应为15%或更多,变化为15%,最小增加量至少为200 ml。后者得出的结果表明,药物方案之间的内部一致性更高。根据这一标准,对沙丁胺醇或泼尼松龙无反应的患者有56例(44%),对沙丁胺醇有反应的71例(包括所有27个类固醇反应者),对5毫克沙丁胺醇无反应(但对200毫克)无反应的患者有25例。一般而言,沙丁胺醇后FEV1的增加最大,发生在泼尼松龙后改善最大的受试者。在泼尼松龙治疗两周后显示FEV1有反应的受试者总症状评分有所下降,这与那些对任何治疗无反应或仅对沙丁胺醇无反应的受试者不同。这些数据表明,在临床上被诊断为患有稳定的慢性阻塞性肺病的患者中,对β激动剂的反应具有可逆性,这种可逆性很严重,最好通过使用大剂量的沙丁胺醇进行检测。沙丁胺醇应答者是口服泼尼松龙试验后最有可能改善的应答者。在低基线值(小于1升)下计算百分比响应时,应考虑到FEV1的可变性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号